News coverage about Arbutus Biopharma Corporation (NASDAQ:ABUS) has trended somewhat positive recently, according to Accern. The research group identifies negative and positive media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Arbutus Biopharma Corporation earned a media sentiment score of 0.22 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 45.1540829558877 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

These are some of the headlines that may have impacted Accern Sentiment’s analysis:

Several brokerages recently commented on ABUS. JMP Securities reissued an “outperform” rating and issued a $13.00 price target (up previously from $12.00) on shares of Arbutus Biopharma Corporation in a research note on Wednesday, October 4th. ValuEngine raised Arbutus Biopharma Corporation from a “sell” rating to a “hold” rating in a research note on Thursday, September 21st. Wedbush reissued an “outperform” rating and issued a $9.00 price target on shares of Arbutus Biopharma Corporation in a research note on Wednesday, September 20th. Chardan Capital reissued a “buy” rating on shares of Arbutus Biopharma Corporation in a research note on Wednesday, September 13th. Finally, Zacks Investment Research raised Arbutus Biopharma Corporation from a “sell” rating to a “hold” rating in a research report on Monday, July 10th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company has an average rating of “Buy” and an average target price of $15.00.

In other news, insider Michael J. Sofia sold 10,000 shares of Arbutus Biopharma Corporation stock in a transaction that occurred on Tuesday, October 3rd. The stock was sold at an average price of $8.00, for a total transaction of $80,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Michael J. Sofia sold 30,000 shares of Arbutus Biopharma Corporation stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $3.70, for a total value of $111,000.00. Following the transaction, the insider now owns 1,563,403 shares of the company’s stock, valued at $5,784,591.10. The disclosure for this sale can be found here. 10.00% of the stock is owned by insiders.

WARNING: “Arbutus Biopharma Corporation (ABUS) Earns Media Impact Score of 0.22” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://www.thecerbatgem.com/2017/10/13/arbutus-biopharma-corporation-abus-earns-media-impact-score-of-0-22.html.

About Arbutus Biopharma Corporation

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

Insider Buying and Selling by Quarter for Arbutus Biopharma Corporation (NASDAQ:ABUS)

Receive News & Stock Ratings for Arbutus Biopharma Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma Corporation and related stocks with our FREE daily email newsletter.